DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/3hmfbc/melanoma_drug) has announced the addition of the "Melanoma Drug Pipeline Update 2014" report to their offering.
Melanoma comprises just 5% of all skin cancers but it is the most deadly. High unmet needs still persist for this tumor type and despite three decades of extensive R&D, five-year survival of advanced patients remains below 20%.
There are today 266 companies plus partners developing 311 drugs targeting melanoma in development. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 130 drugs. Melanoma Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 257 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer.
To date 244 out of the 247 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 59 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Drug Pipeline Update at a Glance
Includes more than 266 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.
Pipeline Breakdown According to Number of Drugs
- Marketed # 21
- Pre-registration # 1
- Phase III # 18
- Phase II # 111
- Phase I # 93
- Preclinical # 66
- No Data # 1
- Suspended # 3
Ceased # 130
Included melanoma drugs are also in development for 234 other indications, where of 128 are different cancer indications.
For more information visit http://www.researchandmarkets.com/research/3hmfbc/melanoma_drug